Alkem Laboratories share price
You have to be logged in to add this to Watchlist.- ₹4,804.60(-0.17%)June 18, 2025 15:52:58 PM IST
- NSE
- BSE
- Vol : 121.04K (NSE + BSE)Last 20 day avg : 372.43 K
Alkem Laboratories is trading -0.17% lower at Rs 4,804.60 as compared to its last closing price. Alkem Laboratories has been trading in the price range of 4,823.10 & 4,776.00. Alkem Laboratories has given -14.57% in this year & -2.94% in the last 5 days. Alkem Laboratories has TTM P/E ratio 26.95 as compared to the sector P/E of 23.94.There are 17 analysts who have initiated coverage on Alkem Laboratories. There are 1 analysts who have given it a strong buy rating & 5 analysts have given it a buy rating. 4 analysts have given the stock a sell rating.The company posted a net profit of 305.86 Crores in its last quarter.Listed peers of Alkem Laboratories include Lupin (0.51%), Abbott India (-0.92%), Alkem Laboratories (-0.17%).The Mutual Fund holding in Alkem Laboratories was at 14.97% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Alkem Laboratories was at 9.40% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Jun 18, 2025, 10:36 PM UTC
- Dividend YieldInline with the industry0.93Annual dividends as a percentage of the stock price.
- P/BIn line with historical values4.80The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values26.58Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.82Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.12The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 7.08% from Rs 3143.75 crore to Rs 2935.82 crore, year-on-year
- The company has grown its March quarter profit by 4.19% from Rs 293.56 crore to Rs 305.86 crore, year-on-year
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 5,323.48
- R2
- 5,551.27
- R3
- 5,835.73
- S1
- 4,811.23
- S2
- 4,526.77
- S3
- 4,298.98
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Lupin | Bearish | 1,953.45 | 0.51 | 89,213.18 | 28.05 | 5.34 | 0.40 | 11.80 |
| Abbott India | Bullish | 31,510.00 | -0.92 | 66,963.61 | 47.59 | 15.9 | 1.50 | 3.73 |
| Alkem Laboratories | Bearish | 4,804.60 | -0.17 | 57,596.39 | 26.88 | 4.86 | 0.92 | 4.83 |
| Glaxosmithkline Pharmaceutical | Bullish | 3,277.35 | 0.77 | 55,765.48 | 61.72 | 29.23 | 1.25 | 0.13 |
| Glenmark Pharmaceuticals | Bullish | 1,659.10 | 0.32 | 46,819.94 | 35.82 | 5.37 | 0.15 | 7.90 |
- Promoter(s) holds a high stake in the company at 55.13%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.74 percentage points from previous quarter
- Mutual Funds holding has increased by 0.96 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-29 | Audited Results & Final Dividend |
| 2025-02-07 | Quarterly Results & Interim Dividend |
| 2024-11-13 | Quarterly Results |
| 2024-08-09 | Quarterly Results |
| 2024-05-29 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE540L01014
- BSE Code539523
- NSE CodeALKEM
Alkem Laboratories is trading at 4804.60 as on Wed Jun 18 2025 10:22:58. This is -0.17% lower as compared to its previous closing price of 4812.65.
The market capitalization of Alkem Laboratories is 57596.39 Cr as on Wed Jun 18 2025 10:22:58.
The average broker rating on Alkem Laboratories is Hold. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 5 analysts have given a buy rating
- 4 analysts have given a hold rating
- 4 analysts have given a sell rating
- 3 analysts have given a strong sell rating
The 52 wk high for Alkem Laboratories is 6440.00 whereas the 52 wk low is 4498.90
Alkem Laboratories can be analyzed on the following key metrics -
- TTM P/E: 26.95
- Sector P/E: 23.94
- Dividend Yield: 0.93%
- D/E ratio: 0.12
Alkem Laboratories reported a net profit of 2165.48 Cr in 2025.
The Mutual Fund Shareholding was 14.97% at the end of 31 Mar 2025.